The series is dedicated to exploring the psychedelic revival and Cultivating a Healthy Mind, Body and Spirit
VANCOUVER, B.C., November 1, 2022 /PRNewswire/ – numinus wellness inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company promoting innovative treatments and evidence-based, safe psychedelic-assisted therapies, today announced the re-launch of “Frontiers of psychedelic therapy,“a podcast series that will now be hosted by the Numinus Clinical Director of Education and Training, dr Stephen Thayerclinical Director, dr Reid-Robinson as much as dr jose flanders, Vice President of Psychology.
Frontiers of psychedelic therapy it was initially launched in 2021 as one of the first podcast offerings of its kind. This day, Frontiers of psychedelic therapy is being relaunched with additional hosts, expanded topics to explore, and a new Numinus brand. The podcast focuses primarily on the professional development of clinicians, but is also designed to appeal to guides, healers, researchers, therapists, and those simply curious about mental, physical, and spiritual health alike. Follow in the footsteps of the previous Numinus podcast series, mindspace, organized by Dr. jose flandersand based on success Frontiers of psychedelic therapy has accomplished since it was originally started by Novamind, which Numinus acquired in june 2022.
“We continue to see encouraging research supporting the efficacy of psychedelic-assisted therapy for a range of mental health issues that are common in today’s society, including depression, post-traumatic stress disorder, anxiety and addiction. There is a great opportunity to share important information, educate potential vendors, and discuss learnings with the wider community. We are excited to relaunch Frontiers of psychedelic therapy to help provide education and community around these important topics,” says dr. Reid Robinson, clinical director of Numinus. “This platform will not only allow us to share the latest advances in psychedelic medicine and our collective discoveries, it will humanize them, providing a more personalized way to connect with our audiences, one conversation at a time.”
Episodes will cover a variety of topics, featuring engaging conversations about psychedelics, the research and therapy that makes them powerful agents for lasting change in mental health. Together, Dr. Thayer, Dr.Robinson Y Dr. Flanders Lead a multitude of conversations with special guests as they explore the frontiers of psychedelic medicine and what it takes to cultivate a healthy mind, body, and spirit.
new episodes of the Frontiers of psychedelic therapy The podcast will launch every Tuesday wherever podcasts are available, including Apple Podcasts, Google Podcasts, Spotify, YouTube and on. numinus.com. Future episodes will cover topics including the practice of effective and ethical psychedelic-assisted psychotherapy, seated travel, harm reduction, equitable access to care, and more, and guests including jon hopkinsGrammy-nominated English electronic music producer, among others.
Listen to Numinus Presents: Frontiers of Psychedelic Therapy:
Apple Podcasts | Youtube | Spotify
ABOUT THE HOSTS:
Reid RobinsonMD MBA – Clinical Director of NUMINUS
Dr. Robison is a board certified psychiatrist. He is an adjunct professor at the University of Utahfounder of the Polizzi Free Clinic and elected Best Psychiatrist in Utah in 2020. Over the past decade, Dr. Robison has led more than 200 clinical trials in neuropsychiatry and is currently the principal investigator for studies evaluating LSD and psilocybin for psychiatric conditions. Most notably, he served as Coordinating Investigator for the Multidisciplinary Association for Psychedelic Studies (MAPS) study of MDMA-Assisted Psychotherapy of Eating Disorders. As an early adopter and researcher of ketamine in psychiatry, Dr. Robison has facilitated thousands of ketamine and Spravato sessions and has trained countless physicians in ketamine-assisted psychotherapy.
Stephen ThayerPhD – Clinical Director, Education and Training for NUMINUS
dr Steve Thayer is a licensed clinical psychologist and psychotherapist. Dr. Thayer began his career in the U.S. Air Force, where he served as Officer-in-Charge of the Barksdale Mental Health Clinic, managed the Barksdale Alcohol and Drug Abuse Prevention and Treatment Program (ADAPT ), provided therapeutic and evaluation services, and advised the military. leadership on community mental health issues. Since leaving the military, Dr. Thayer has specialized in psychedelic-assisted psychotherapy and is the lead facilitator for several ongoing psychedelic medicine clinical trials. Dr. Thayer is an adjunct professor who teaches undergraduate and graduate courses in counseling skills, clinical psychology, and personality theory. Dr. Thayer is a ketamine-assisted psychotherapy supervisor and trainer and co-host of the Psychedelic Therapy Frontiers podcast.
jose flandersPh. D. OPQ – NUMINUS Vice President of Psychology
dr jose flanders is a licensed psychologist, with an active practice in psychotherapy, mindfulness, and psychedelic-assisted therapy. She currently provides ketamine-assisted, psilocybin-assisted, and MDMA-assisted therapy. She is the head of professional training at Numinus and has certifications as a teacher and teacher trainer in Mindfulness-Based Stress Reduction and Mindfulness-Based Cognitive Therapy. Joe has been on a lifelong journey in search of the most effective approaches to cultivating wellness, his own and that of his clients. In the last decade of that journey, Joe has served as Founder and Director of mind spacea wellness center with several locations and more than 35 mental health professionals in Montreal.
About Numinus
Numinus Wellness (TSX: NUMI) helps people heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model, which includes psychedelic production, research, and clinical care, is at the forefront of a transformation aimed at healing rather than controlling symptoms of depression, anxiety, trauma, pain, and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.
Learn more at numinus.com and follow us on LinkedIn, Facebook, TwitterY Instagram.
Disclaimer
Neither Numinus Wellness Inc. nor any of its subsidiaries is a professional corporation licensed to practice health services. In jurisdictions where health services may only be provided by a corporation if that corporation has a valid permit to do so, Numinus and its subsidiaries operate in a management services role for affiliated professional corporations, which provide health services to patients. Numinus and its subsidiaries provide health services directly to patients in those jurisdictions where they are authorized to do so.
Forward-looking statements
This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including, without limitation, statements about future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs about future performance are “forward-looking statements.” Forward-looking statements can be identified by the use of words such as “expects”, “does not expect”, “is expected”, “believes”, “intends”, “anticipates”, “does not anticipate”, “believes”. or variations of these words, expressions or statements, that certain actions, events or results “may”, “could”, “would”, “could” or “will” be taken, occur or be performed. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results, events or developments to differ materially from expected results, events or developments expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the reliance on obtaining and maintaining regulatory approvals, including the acquisition and renewal of federal, provincial, state, municipal, local or other licenses, and any inability to obtain all government authorizations and licenses. necessary. and permits to operate and expand the Company’s facilities; regulatory or policy changes, such as changes in applicable laws and regulations, including federal, state, and provincial legalization, due to fluctuations in public opinion, industry perception of integrative mental health, including the use of psychedelics, delays or inefficiencies or any other reason; any other factors or developments that may hamper the growth of the market; the Company’s limited operating and profitability history; management dependency; the Company’s need for additional financing and the effects of financial market conditions and other factors on the availability of capital; competition, including from more established and better financed competitors; the impact of Russia–Ukraine conflict in the global economy; the continuing impact of the COVID-19 pandemic; and the need to build and maintain alliances and partnerships, including with research and development companies, customers, and suppliers. These factors should be carefully considered and readers are cautioned not to place undue reliance on forward-looking statements. Despite the Company’s efforts to identify major risk factors that could cause actual measures, events or results to differ materially from those described in forward-looking statements, other risk factors may cause actual measures, events or developments to differ. materially from those anticipated, estimated or intended. There can be no guarantee that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company does not undertake to revise any forward-looking statements, even if new information becomes available as a result of future events, new facts or for any other reason, except as required by applicable law.
See original content:https://www.prnewswire.com/news-releases/numinus-re-launches-psychedelic-therapy-frontiers-podcast-with-additional-hosts-and-topics-301664087.html
SOURCE Numinus Wellness Inc.
